Mobius Theraputics™ Granted Orphan Drug Designation

Published: Jan 23, 2008

ST. LOUIS, MO--(Marketwire - January 23, 2008) - Mobius Therapeutics, Inc.™ has been granted orphan drug designation for its platform product, Trabomycin™, by the Office of Orphan Products Development of the U.S. Food and Drug Administration. This approval grants seven years of U.S. market exclusivity to Mobius, once its New Drug Application is approved.

Back to news